Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations
Open Access
- 19 July 2023
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-17
Abstract
Diffuse large B-cell lymphoma (DLBCL) represents the commonest subtype of non-Hodgkin lymphoma and encompasses a group of diverse disease entities, each harboring unique molecular and clinico-pathological features. The understanding of the molecular landscape of DLBCL has improved significantly over the past decade, highlighting unique genomic subtypes with implications on targeted therapy. At the same time, several new treatment modalities have been recently approved both in the frontline and relapsed settings, ending a dearth of negative clinical trials that plagued the past decade. Despite that, in the real-world setting, issues like drug accessibility, reimbursement policies, physician and patient preference, as well as questions regarding optimal sequencing of treatment options present difficulties and challenges in day-to-day oncology practice. Here, we review the recent advances in the therapeutic armamentarium of DLBCL and discuss implications on the practice landscape, with a particular emphasis on the context of the healthcare system in Singapore.Keywords
Funding Information
- Singapore Ministry of Health’s National Medical Research Council Research Transition Award (TA21jun-0005)
- Singapore Ministry of Health’s National Medical Research Council Collaborative Centre Grant (CG21APR2002)
- Tanoto Foundation Professorship in Medical Oncology
- New Century Foundation Limited
- LING Foundation
- Singapore Ministry of Health’s National Medical Research Council Large Collaborative Grant (OFLCG18May-0028)
This publication has 139 references indexed in Scilit:
- Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic optionsAnnals of Oncology, 2013
- CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupThe Lancet Oncology, 2011
- Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With RituximabJournal of Clinical Oncology, 2011
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'AdulteBlood, 2010
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI)British Journal of Haematology, 2010
- Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaBlood, 2010
- The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphomaBlood, 2010
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995